Related Experiment Videos
sFas and sFas ligand and pediatric sepsis-induced multiple organ failure syndrome
Lesley Doughty1, Robert S B Clark, Sandra S Kaplan
1Department of Pediatrics, Rhode Island Hospital, Providence, Rhode Island 02903, USA.
Abstract:
The Fas-Fas ligand system is important for apoptosis of activated immune cells. Perturbation of this system occurs in diseases with dysregulated inflammation. Increased soluble Fas (sFas) occurs in systemic inflammatory response syndrome (SIRS) and can block apoptosis. Increased shedding of FasL (sFasL) occurs in viral infection and hepatitis. Although dysregulated inflammation is associated with sepsis-induced multiple organ failure (MOF) in children, a role for Fas has not been established. We hypothesize that 1) sFas will be increased in children with severe and persistent sepsis-induced MOF and will correlate with inflammatory markers suggesting a role for sFas in inflammatory dysregulation in severe sepsis, and 2) sFasL will be increased when viral sepsis or sepsis-induced liver failure-associated MOF is present in children. Plasma sFas, sFasL, IL-6, IL-10, nitrite + nitrates, and organ failure scores were measured on d 1 and d 3 in 92 children with severe sepsis and 12 critically ill control children. sFas levels were increased in severe sepsis, continued to increase in persistent MOF and nonsurvivors, and were correlated with serum inflammatory markers (IL-6, IL-10, nitrite + nitrate levels). In contrast, sFasL was not increased in severe sepsis and did not correlate with inflammation. sFasL was, however, increased in liver failure-associated MOF and in nonsurvivors, and was associated with viral infection. At autopsy, hepatocyte destruction and lymphocyte infiltration were associated with increased sFas and sFasL levels. sFas may interfere with activated immune cell death and contribute to dysregulation of inflammation, worsening outcome from severe sepsis. sFasL may contribute to hepatic injury and the development of liver failure-associated MOF.
Insights
Soluble Fas (sFas) increases in severe sepsis, potentially blocking immune cell death and worsening inflammation. Soluble Fas ligand (sFasL) rises with liver failure and viral sepsis, contributing to hepatic injury in critically ill children.
Area of Science:
- Immunology
- Pediatric Critical Care
- Molecular Biology
Background:
- The Fas-Fas ligand system regulates immune cell apoptosis, crucial for controlling inflammation.
- Dysregulation of this system is implicated in inflammatory diseases.
- The role of Fas in pediatric sepsis-induced multiple organ failure (MOF) remains unclear.
Purpose of the Study:
- To investigate the levels and significance of soluble Fas (sFas) and soluble Fas ligand (sFasL) in children with severe sepsis and MOF.
- To determine the correlation of sFas and sFasL with inflammatory markers and clinical outcomes.
- To explore the association of sFasL with viral sepsis and liver failure-associated MOF.
Main Methods:
- Plasma levels of sFas, sFasL, IL-6, IL-10, and nitrite/nitrates were measured in 92 children with severe sepsis and 12 controls.
- Organ failure scores were assessed on days 1 and 3.
- Autopsy findings were analyzed in relation to sFas and sFasL levels.
Main Results:
- Elevated sFas levels were observed in severe sepsis, increasing with persistent MOF and in non-survivors, correlating with inflammatory markers.
- sFasL was not elevated in general severe sepsis but increased in liver failure-associated MOF, non-survivors, and viral infections.
- Autopsies revealed hepatocyte destruction and lymphocyte infiltration associated with higher sFas and sFasL.
Conclusions:
- Increased sFas may impair immune cell apoptosis, contributing to inflammatory dysregulation and poor outcomes in pediatric sepsis.
- Elevated sFasL is linked to hepatic injury and liver failure in sepsis, particularly in viral cases.
- The Fas pathway plays a significant role in the pathogenesis of severe sepsis and MOF in children.
Related Concept Videos
Acute Inflammation III: Local and Systemic Effects
Heart Failure II: Pathophysiology